| 27.31 0.11 (0.4%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 42.56 | 1-year : | 49.48 |
| Resists | First : | 36.44 | Second : | 42.36 |
| Pivot price | 35.18  |
|||
| Supports | First : | 26.85 | Second : | 22.33 |
| MAs | MA(5) : | 28.85 |
MA(20) : | 35.64 |
| MA(100) : | 36.89 |
MA(250) : | 44.31 |
|
| MACD | MACD : | -2 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 3.8 |
D(3) : | 5.3 |
| RSI | RSI(14): 27.5 |
|||
| 52-week | High : | 60.36 | Low : | 26.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RARE ] has closed above bottom band by 8.7%. Bollinger Bands are 213.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 27.77 - 27.96 | 27.96 - 28.12 |
| Low: | 26.68 - 26.92 | 26.92 - 27.13 |
| Close: | 26.95 - 27.32 | 27.32 - 27.65 |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Wed, 16 Jul 2025
William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) - MSN
Tue, 15 Jul 2025
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA - Zacks Investment Research
Tue, 15 Jul 2025
Ultragenyx: The High Stakes Of Binary Events And A Short Cash Runway (RARE) - Seeking Alpha
Mon, 14 Jul 2025
Ultragenyx hit again, this time with a CRL in rare disease - BioWorld MedTech
Mon, 14 Jul 2025
FDA rejects Ultragenyx rare disease gene therapy around manufacturing issues - San Francisco Business Times - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 95 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 98.4 (%) |
| Shares Short | 6,080 (K) |
| Shares Short P.Month | 5,890 (K) |
| EPS | -5.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.53 |
| Profit Margin | -93.1 % |
| Operating Margin | -102.7 % |
| Return on Assets (ttm) | -24.6 % |
| Return on Equity (ttm) | -377.1 % |
| Qtrly Rev. Growth | 28 % |
| Gross Profit (p.s.) | -1.93 |
| Sales Per Share | 6.24 |
| EBITDA (p.s.) | -5.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -390 (M) |
| Levered Free Cash Flow | -173 (M) |
| PE Ratio | -4.69 |
| PEG Ratio | 0 |
| Price to Book value | 17.73 |
| Price to Sales | 4.37 |
| Price to Cash Flow | -6.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|